

Applicants: Jingrong Cao et al.  
Application No.: 10/696,862

## REMARKS

### The Claim Amendments

Claim 1 has been amended to recite a compound of formula I, wherein Q<sup>1</sup> is -CO-, Q<sup>2</sup> is -(CHR<sup>6</sup>)<sub>1-3</sub>-, and Ring B is selected from several thiophene and thiazole moieties. Support for this amendment is found in the specification in paragraphs [0082] and [0083] on page 45 and in original claims 34 and 35. As a consequence of the amended definitions for Q<sup>1</sup>, Q<sup>2</sup>, and Ring B, the scope of the disclaimed subject matter has been redefined to delete compounds that are no longer encompassed by claim 1.

Claims 2-3, 7, 13, and 21-22 have been canceled.

Claims 4-6, 8, 14, 16, and 20 have been amended to depend from non-canceled claims. Support for these amendments is in the claims as originally filed.

Claim 45 has been amended to correspond the scope of this claim to amended claim 1. Support for this amendment is found in the claim as originally filed.

None of the amendments adds new matter. Their entry is requested.


These claim amendments are made expressly without waiver of applicants' rights to continue to prosecute and to obtain claims to the canceled subject matter either in this application or in other applications claiming benefit herefrom.

### The Response


#### *Rejection under 35 U.S.C. § 102(b)*

The Examiner has rejected claims 1-6 and 21-27 under 35 U.S.C. § 102(b) for allegedly being anticipated by Che et al., Yingyong Huaxue 19(8), 795-797, 2002 (hereafter, "Che"), which describes the compound having Chemical Abstracts Registry No. [474327-31-6]:

Applicants:           Jingrong Cao et al.  
Application No.:       10/696,862



[474327-38-3]



[474327-31-6].

Applicants traverse. The compound cited by the Examiner was disclaimed in claim 1 as originally filed. See Section I) A) i). Furthermore, compound no. [474327-31-6] is not encompassed by the scope of the amended claims. Thus, applicants respectfully request that the Examiner withdraw the rejection of claims 1-6 and 21-27 over 35 U.S.C. § 102(b).

*Rejection under 35 U.S.C. § 103(a)*


The Examiner has rejected claims 1-6 and 21-27 under 35 U.S.C. § 103(a) for allegedly being obvious in view of the compound nos. [474327-38-3] and [474327-31-6] of Che (see above). Applicants have amended claim 1 and claims dependent thereon to recite compounds of formula I, wherein Ring B is a thiophene or thiazole. These compounds are neither described nor suggested by Che. Accordingly, applicants respectfully request that the Examiner withdraw the rejection of claims 1-6 and 21-27 over 35 U.S.C. § 103(a).

Applicants: Jingrong Cao et al.  
Application No.: 10/696,862

Conclusion

Applicants request that the Examiner enter the above amendments, consider the accompanying arguments, and allow the claims to pass to issue. Should the Examiner deem expedient a telephone discussion to further the prosecution of the above application, applicants request that the undersigned be contacted at the Examiner's convenience.

Respectfully submitted,



---

Daniel A. Pearson (Reg. No. 58,053)

Agent for Applicants

Karen E. Brown (Reg. No. 43,866)

Attorney for Applicants

c/o Vertex Pharmaceuticals Incorporated

130 Waverly Street

Cambridge, MA 02139-4242

Tel.: (617) 444-6790

Fax.: (617) 444-6483